The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy
Open accessAbstract
Alterations in phosphorylation of cellular proteins are a hallmark of malignant transformation. Degradation of these phosphoproteins could generate cancer-specific class I MHC-associated phosphopeptides recognizable by CD8 + T lymphocytes. In a comparative analysis of phosphopeptides presented on the surface of melanoma, ovarian carcinoma, and B lymphoblastoid cells, we find 5 of 36 that are restricted to the solid tumors and common to both cancers. Differential presentation of these peptides can result from differential phosphorylation of the source proteins. Recognition of the peptides on cancer cells by phosphopeptide-specific CD8 + T lymphocytes validates the potential of these phosphopeptides as immunotherapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry
Syka, J. E. P., Coon, J. J., Schroeder, M. J., Shabanowitz, J., & Hunt, D. F. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402700101 · Cited by 2,370
Self-citationReplacing the complementarity-determining regions in a human antibody with those from a mouse
Jones, P. T., Dear, P. H., Foote, J., Neuberger, M. S., & Winter, G. (1986) · Nature · doi:10.1038/321522a0 · Cited by 1,406
Haurum, J. S., Arsequell, G., Lellouch, A. C., Wong, S. Y., Dwek, R. A., McMichael, A. J., & Elliott, T. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.2.739 · Cited by 184
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
More than one reason to rethink the use of peptides in vaccine design
Purcell, A. W., McCluskey, J., & Rossjohn, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2224 · Cited by 860
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire
Ostrov, D. A., Grant, B. J., Pompeu, Y. A., Sidney, J., Harndahl, M., Southwood, S., Oseroff, C., Lu, S., Jakoncic, J., de Oliveira, C. A. F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207934109 · Cited by 421
Self-citationDeep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 307
Metadata
- Authors
- Zarling, A. L., Polefrone, J. M., Evans, A. M., Mikesh, L. M., Shabanowitz, J., Lewis, S. T., Engelhard, V. H., & Hunt, D. F.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-10-03
- Volume
- 103
- Issue
- 40
- Pages
- 14889-14894
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2026506656
- Cited by
- 193
- References
- 4
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. https://app.cochat.ai/papers/10.1073/pnas.0604045103
- The paper
- Zarling, A. L., Polefrone, J. M., Evans, A. M., Mikesh, L. M., Shabanowitz, J., Lewis, S. T., Engelhard, V. H., & Hunt, D. F. (2006). Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0604045103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.